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SUMMARY
Cellular DNA damage response (DDR) involves dramatic
transcriptional alterations, the mechanisms of which remain
ill-defined. Given the centrality of RNA polymerase II (Pol II)
promoter-proximal pause release in transcriptional control,
we evaluated its importance in DDR. Here we show that
following genotoxic stress, the RNA-binding motif protein 7
(RBM7) stimulates Pol II elongation and promotes cell
viability by activating the positive transcription elongation
factor b (P-TEFb). This is mediated by genotoxic stress-
enhanced binding of RBM7 to 7SK snRNA (7SK), the scaffold
of the 7SK small nuclear ribonucleoprotein (7SK snRNP)
which inhibits P-TEFb. In turn, P-TEFb relocates from 7SK
snRNP to chromatin to induce transcription of short units
including key DDR genes and multiple classes of non-
coding RNAs. Critically, interfering with RBM7 or P-TEFb
provokes cellular hypersensitivity to DNA damage-inducing
agents through activation of apoptotic program. By
alleviating the inhibition of P-TEFb, RBM7 thus facilitates Pol
II elongation to enable a pro-survival transcriptional
response that is crucial for cell fate upon genotoxic insult.
Our work uncovers a new paradigm in stress-dependent
control of Pol II pause release, and offers the promise for
designing novel anti-cancer interventions using RBM7 and
P-TEFb antagonists in combination with DNA-damaging
chemotherapeutics.
INTRODUCTION
Cellular DDR has evolved to detect and repair lesions that are
generated continuously by external and internal DNA-damaging
agents (Hoeijmakers, 2009). In parallel, activation of DDR halts
progression of the cell-cycle to provide time for repair, of which
outcome determines whether cells will re-enter the cell-cycle and
continue with their physiological program or die by senescence
or apoptosis. Defective DDR can lead to genomic instability
underlying many diseases, including hematological disorders
and cancer (Jackson and Bartek, 2009). Importantly, it is widely
accepted that cells need to shut down Pol II transcription in
response to ultraviolet light (UV)-induced bulky DNA lesions and
other types of DNA damage, which can facilitate the repair and
limit the production of abnormal transcripts (Giono et al., 2016).
While transcription can be inhibited transiently at initiation and
elongation stages (Awwad et al., 2017; Rockx et al., 2000;
Williamson et al., 2017), or irreversibly through degradation of
stalled Pol II (Wilson et al., 2013), it is eventually restored once
the damage is corrected. However, mechanisms and significance
of mounting transcriptional activation following genotoxic stress
remain poorly understood.
Transition of Pol II from promoter-proximal pausing to
productive elongation represents a critical rate-limiting step in
metazoan gene expression (Jonkers and Lis, 2015; Zhou et al.,
2012). At most active genes, Pol II transcribes 20-100
nucleotides from transcription start site before productive
elongation is paused by the multi-subunit negative transcription
elongation factors (N-TEFs), consisting of negative elongation
factor (NELF) and DRB-sensitivity inducing factor (DSIF). The
release of paused Pol II genome-wide is stimulated by P-TEFb
kinase, which is composed of the catalytic CDK9 and a regulatory
CycT1 or CycT2 subunit (Gressel et al., 2017; Jonkers et al.,
2014; Mayer et al., 2015; Peterlin and Price, 2006). Upon its
recruitment or activation at target gene promoters or enhancers,
P-TEFb phosphorylates serine 2 residues (Ser2-P) within the C-
terminal domain (CTD) Y1S2P3T4S5P6S7 heptapeptide repeats of
the largest Pol II subunit RPB1, as well as NELF-E and the SPT5
subunit of DSIF, leading to productive Pol II elongation (Jonkers
and Lis, 2015; McNamara et al., 2016; Quaresma et al., 2016;
Zhou et al., 2012). In addition, clearance of Pol II from promoter-
proximal pause sites enables new transcriptional initiation,
augmenting the production of RNA (Gressel et al., 2017; Shao
and Zeitlinger, 2017).
Considering that P-TEFb is crucial for prompt expression of
stimulus-induced genes (Liu et al., 2015), we reasoned that it
might feature prominently in stimulating Pol II transcription
following DNA damage. Importantly, a major fraction of P-TEFb
resides within 7SK snRNP, in which coordinated actions of the
scaffolding 7SK and three canonical RNA binding proteins
(RBPs) inhibit the kinase. While the 7SK g -methylphosphate
capping enzyme (MePCE) and La-related protein 7 (LARP7)
stabilize 7SK to form the core of 7SK snRNP, HEXIM1 or its
paralogue HEXIM2 subsequently interacts with 7SK of the core
to bind and inhibit P-TEFb (Guo and Price, 2013; Quaresma et
al., 2016). Of note, activation of P-TEFb through its release from
7SK snRNP, as exemplified most prominently by the RNA
binding HIV-1 transcriptional transactivator Tat, has emerged as
a key regulatory event that stimulates Pol II pause release at
specific genes (Quaresma et al., 2016). Given that cellular RBPs
are emerging as important effectors in DDR (Dutertre et al., 2014;
Wickramasinghe and Venkitaraman, 2016) and transcription
(Quaresma et al., 2016; Skalska et al., 2017), we reasoned that
a protein from this class could mediate genotoxic stress-induced
P-TEFb activation and thus Pol II transcription via 7SK snRNP.
In this study, we focused our efforts on the ubiquitously
expressed RBM7, which promotes survival of cells following DNA
damage generated by UV or its mimicking genotoxic and
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carcinogenic chemical 4-nitroquinoline 1-oxide (4-NQO) (Blasius
et al., 2014). RBM7 binds the DExH/D box RNA helicase hMTR4
(also known as SKIV2L2) through the bridging zinc knuckle
protein ZCCHC8, forming the nuclear exosome targeting
complex (NEXT) (Falk et al., 2016; Lubas et al., 2011). Through
the RNA-binding capacity of RBM7, NEXT promotes degradation
of multiple RNA classes, including upstream antisense (uaRNAs)
and enhancer-derived (eRNAs) transcripts, as well as 3′ end
extended forms of snRNAs, snoRNAs and histone gene
transcripts (Andersen et al., 2013; Hallais et al., 2013; Hrossova
et al., 2015; Lubas et al., 2011). Furthermore, NEXT targets pre-
mRNAs for decay and/or processing of intron-embedded
snoRNAs and miRNAs (Lubas et al., 2015), possibly via the
interaction between RBM7 and spliceosomal SF3b complex
(Falk et al., 2016).  Finally, NEXT associates with the cap-binding
protein complex and functions in connecting transcription
termination with exosomal degradation (Andersen et al., 2013;
Hallais et al., 2013). Although the linkage between RBM7 and
DDR has been reported (Blasius et al., 2014), it remains unclear
how does RBM7 exert its pro-survival function. Here we
uncovered an unexpected interplay between RBM7 and 7SK
snRNP in the wake of DNA damage, shining a spotlight on the
central role of P-TEFb kinase in shaping a transcriptional
response that is crucial for viability of genotoxic-stressed cells.
RESULTS
iCLIP reveals DNA damage-enhanced interaction between
RBM7 and 7SK
The vital role of RBM7 in DDR led us to postulate that defining
the RNA interactome of RBM7 under unchallenged and DNA
damage conditions should disclose insights into the mechanisms
underlying its critical function in genotoxic-stressed cells. Thus,
we performed individual-nucleotide resolution UV crosslinking
and immunoprecipitation (iCLIP) assay in human HEK 293 Flp-
In T-Rex (HEK 293) cells that expressed 3X-FLAG epitope-
tagged RBM7 (F-RBM7). Because UV irradiation yields RNA-
protein crosslinks immediately and thus prior to DDR activation,
we instead employed its mimetic 4-NQO. Notably, 4-NQO
metabolite 4-hydroxyaminoquinolone 1-oxide forms bulky DNA
adducts on purines, which are removed by nucleotide excision
repair (Ikenaga et al., 1977; Tada and Tada, 1976). Consistent
with the previous report (Lubas et al., 2015), RBM7 bound a
diverse set of RNAs, including genic, intergenic and non-coding
(nc) RNAs (Figures 1A and S1). We ranked these RNAs by the
change in binding following 4-NQO exposure, which showed
increased RBM7 binding to snRNAs, including 7SK,
spliceosomal snRNAs, and other ncRNAs, and decreased RBM7
binding to specific pre-mRNAs (Tables S1 and S2). As expected,
4-NQO exposure led to a dramatic increase in g-H2AX foci
formation, confirming activation of DDR (Figure S2A). Given the
pivotal role of 7SK snRNP in regulating Pol II pause release
(McNamara et al., 2016; Quaresma et al., 2016), we set out to
investigate the potential connection between RBM7 and 7SK in
controlling Pol II transcription following genotoxic stress.
We next plotted the RBM7 iCLIP reads on the secondary
structure model of 7SK. This revealed that RBM7 binds
selectively stem-loop 3 (SL3) of 7SK (Figure 1B), thereby placing
it between MePCE/HEXIM1 and LARP7 that bind the SL1 and
SL4, respectively. Quantitative RNA immunoprecipitation (RIP-
qPCR) assays proved the iCLIP result to be specific since
substituting the conserved Lys60, Phe62 and Phe64 residues of
the ribonucleoprotein 1 (RNP1) motif within the RNA recognition
motif (RRM) of RBM7 to alanines (mRNP1) abrogated the
interaction (Figure 1C). Furthermore, we confirmed that 4-NQO
exposure increased the binding of RBM7 with 7SK, while it
decreased its binding with the uaRNA of RBM39 (Figure 1D),
which is consistent with the DNA damage-induced release of
uaRNAs from NEXT (Blasius et al., 2014; Tiedje et al., 2015).
These results identify RBM7 as a novel 7SK-interacting protein
and suggest a possible role of RBM7 in facilitating the cellular
response to genotoxic stress via 7SK snRNP.
DNA damage stimulates the relocation of P-TEFb and
RBM7 from 7SK snRNP to Pol II
To test if RBM7 binds the 7SK snRNP, we performed a co-
immunoprecipitation (co-IP) analysis in HEK 293 cells. This
revealed the interaction of F-RBM7 with endogenous LARP7 and
CDK9, but not HEXIM1 (Figure 1E). Importantly, 4-NQO
treatment triggered the release of endogenous CDK9, HEXIM1
and RBM7 from the 7SK snRNP in HEK 293 and HeLa Flp-In
(HeLa) cells, as determined by co-IP analysis with 3X-FLAG
epitope-tagged LARP7 (F-LARP7) as the bait and by glycerol
gradient centrifugation analysis, respectively (Figures 1F and
S2B). Likewise, exposing HeLa cells to UV and primary human
foreskin fibroblasts (HFF-1) to 4-NQO released CDK9 from
HEXIM1 (Figures S2C and S2D).
To follow the relocation of P-TEFb upon genotoxic stress
further, we examined its interaction with RBM7 and Pol II by
conducting a series of co-IP and bimolecular fluorescence
complementation (BiFC) assays. 4-NQO treatment enhanced the
interaction of 3X-FLAG epitope-tagged CDK9 (F-CDK9) with
RBM7 (Figure 1G), suggesting that the initial enhanced binding
between RBM7 and 7SK is followed by the release of RBM7 in
complex with P-TEFb. Notably, interaction of the released
F-CDK9 with the transcriptionally engaged Ser2-P form of Pol II
increased following DNA damage (Figures 1G). Likewise, 4-NQO
treatment enhanced the binding between F-CDK9 and total Pol II
(Figure S3A). To extend these findings, we monitored the
interaction between P-TEFb and the CTD of Pol II in living HeLa
cells using the visualization of P-TEFb activation assay (Fujinaga
et al., 2015). In this approach, BiFC of transiently expressed
YC-P-TEFb and YN-CTD chimera containing the C- and N-
terminal region of yellow fluorescent protein (YFP), respectively,
indicates the interaction (Figure S3B). 4-NQO exposure
increased the number of YFP-positive cells to a similar extent as
the known P-TEFb releasing agents SAHA and JQ1
(Bartholomeeusen et al., 2012; Contreras et al., 2009), which
corroborated our co-IP results (Figures S3C and S3D). These
findings establish that RBM7 binds 7SK snRNP, and that upon
genotoxic stress, P-TEFb relocates to the CTD of Pol II.
RBM7 releases P-TEFb from the core of 7SK snRNP upon
DNA damage
Based on the observations gathered thus far, we hypothesized
that following DNA damage, RBM7 activates P-TEFb by
promoting its release from the 7SK snRNP. As part of NEXT,
RBM7 could recruit the exosome to 7SK snRNP, resulting in its
disintegration via 7SK nucleolysis. However, as determined by
co-IP and RIP-qPCR experiments, the 4-NQO-induced release
of CDK9 and HEXIM1 from F-LARP7 left the core of 7SK snRNP
intact (Figure 2A). Namely, F-LARP7 and MePCE remained
bound during DDR (Figure 2A), and neither the total nor the
LARP7-bound levels of 7SK were altered considerably (Figure
2B). Confirming integrity of the core, we detected its increased
association with hnRNP1 A1 (Figure 2A), which binds 7SK as it
replaces P-TEFb and HEXIM1 during transcriptional inhibition
(Quaresma et al., 2016; Zhou et al., 2012). Conversely, the levels
of HEXIM1-bound 7SK decreased as anticipated (Figure 2B).
Unlike the reconstitution of 7SK snRNP upon removing a P-TEFb
inhibitor flavopiridol (FP) from cell culture medium, the washout
of 4-NQO did not induce re-sequestration of CDK9 and HEXIM1
into the 7SK snRNP, most likely due to the remaining DNA
damage as suggested by the persisting levels of phosphorylated
g-H2AX (Figures 2A and S4). Thus, RBM7 does not employ the
RNA exosome to activate P-TEFb.
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Figure 1. DNA damage induces the interaction of RBM7 with 7SK and relocation of P-TEFb from 7SK snRNP to Pol II.
(A) Distribution charts of unique tags derived from the mock and 4-NQO treated RBM7 libraries based on percentages of the total iCLIP reads and
mapped to the indicated RNA classes. Charts on the right show distribution of the indicated types of ncRNA.
(B) 3X-FLAG epitope-tagged RBM7 protein (F-RBM7) iCLIP reads mapped to 7SK. Positions of the four stem–loops (SL1–4) are indicated below the
iCLIP reads and on a 7SK secondary structure model.
(C) Quantitative RNA immunoprecipitation (RIP-qPCR) of 7SK in WT and mRNP1 F-RBM7 immuno-purifications from HEK 293 whole-cell extracts
(WCE). RBM7 with RRM (in pink) and the position of RNP1 (white stripe) is depicted on top.
(D) RIP-qPCR of 7SK and uaRBM39 in F-RBM7 immuno-purifications from HEK 293 WCE. Conditions with (red bars) and without (blue bars) 4-NQO
are shown. Results in C and D are presented as the mean ± s.e.m. (n = 3 independent experiments). **, P < 0.01. (E,F) Co-immunoprecipitation of F-
RBM7 and 3X-FLAG epitope-tagged LARP7 protein (F-LARP7) with 7SK snRNP from HEK 293 WCE. Conditions with (+) and without (-) 4-NQO are
shown.
(G) Co-immunoprecipitation of 3X-FLAG epitope-tagged CDK9 protein (F-CDK9) with the indicated proteins from HEK 293 WCE. Conditions with (+)
and without (-) 4-NQO are shown.
Alternatively, RBM7 could act on 7SK snRNP directly to
release P-TEFb during DDR. To determine if RBM7 is critical for
the release, we depleted it using RNA interference (RNAi).
Indeed, the 4-NQO-induced release of CDK9 from 3X-FLAG
epitope-tagged HEXIM1 (F-HEXIM) was abrogated in RBM7
knockdown cells (Figure 2C). In a complementary approach,
inducible expression of F-RBM7 in HEK 293 cells decreased the
interactions of endogenous HEXIM1 with CDK9 and 7SK, but this
effect was diminished when using the 7SK binding-deficient
mRNP1 F-RBM7 (Figure 2D). Finally, we examined if RBM7
released CDK9 from 7SK snRNP in vitro by using a P-TEFb
release assay (Figure 2E). We immuno-purified the wild-type
(WT) and mRNP1 F-RBM7 from HEK 293 cells under stringent
conditions to strip-off its binding partners including subunits of
NEXT, RNA exosome and P-TEFb (Figure 2F). Next, we
incubated increasing amounts of the F-RBM7 proteins with the
immobilized 7SK snRNP isolated from HeLa cells using an anti-
HEXIM1 antibody. Confirming our prediction, F-RBM7 released
CDK9 and 7SK from HEXIM1, while the mRNP1 F-RBM7 failed
to do so (Figure 2F). Together, these results show that following
genotoxic stress, RBM7 can release P-TEFb from the core of
7SK snRNP directly.
P-TEFb directs transcriptional activation by Pol II in
response to genotoxic stress
To disclose if active P-TEFb is vital for shaping a transcriptional
response to genotoxic stress, we sequenced newly transcribed
RNAs under unchallenged and DNA damage conditions.
Because the onset of P-TEFb activation occurs within two hours
of genotoxic stress (Figure 2A), we treated HeLa cells for one
and two hours with 4-NQO. During the last 30 minutes, we
labeled transcripts with the nucleoside analogue 4-thiouridine
(4sU), which enables their isolation and sequencing (4sU-seq)
(Figure 3A). Concurrently with 4-NQO, we also exposed the cells
to a sub-optimal concentration of FP to evaluate if
pharmacological inhibition of P-TEFb attenuates the response.
Based on the reproducible 4sU-seq data (Figure S5), we
determined differentially expressed (DE) mRNAs, long intergenic
non-coding (linc) RNAs, uaRNAs and enhancer-derived eRNAs
(p-value ≤ 0.01; expression fold-change ≥ 2; Tables S3-S6). This
revealed that over a third of the DE coding genes and most of the
DE ncRNAs are up-regulated (Figures 3A and 3B).   Importantly,
the stimulated Pol II transcription, which was similar at both
durations of 4-NQO treatments (r=0.81 for eRNAs to 0.89 for
uaRNAs;  Figure S6),  was highly  dependent  on  active  P-TEFb
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Figure 2. RBM7 releases P-TEFb from the core of 7SK snRNP upon DNA damage.
(A) Co-immunoprecipitation of 3X-FLAG epitope-tagged LARP7 protein (F-LARP7) with 7SK snRNP and g-H2AX from HEK 293 WCE. Conditions with
(in hours) and without (-) 4-NQO are shown.
(B) RT-qPCR of 7SK (left) and RIP-qPCR of 7SK in F-LARP7 (middle) and HEXIM1 (right) immuno-purifications (IP) from HEK 293 WCE. Conditions
with (red bars) and without (blue bars) 4-NQO are shown. Results are presented as the mean ± s.e.m. (n = 2 independent experiments). Protein levels
in the IP are shown below the graphs.
(C) Co-immunoprecipitation of 3X-FLAG epitope-tagged HEXIM1 protein (F-HEXIM1) with CDK9 and RBM7 from HEK 293 WCE. Conditions with
control (-) and RBM7 siRNA #1 (+), and with (+) and without (-) 4-NQO are shown.
(D) (Left) Co-immunoprecipitation of HEXIM1 with CDK9 from HEK 293 WCE containing WT and mRNP1 F-RBM7. Conditions with (+) and without (-
) F-RBM7 induction by tetracycline (Tet) are shown. (Right) RIP-qPCR of 7SK in HEXIM1 IP from HEK 293 WCE containing WT and mRNP1 F-RBM7.
Conditions with WT (red bars), mRNP1 (black bars) and without (blue bars) F-RBM7 induction by tetracycline (Tet) are shown. Results are presented
as the mean ± s.e.m. (n = 3 independent experiments). *, P < 0.05, determined by Student's t test.
(E) Cartoon depicting P-TEFb release assay. Release of inactive P-TEFb (CDK9 in red) from 7SK snRNP abrogates the interaction of HEXIM1 with
P-TEFb, resulting in P-TEFb activation (CDK9 in green).
(F) (Left) Eluates of immuno-purified WT and mRNP1 F-RBM7 from HEK 293 WCE. (Middle) Western blot analysis of P-TEFb release from HEXIM1
immuno-purified (aHEXIM1 IP) 7SK snRNP by the F-RBM7 proteins. Control (-, lanes 1 and 2) and conditions with (+) increasing amounts of WT and
mRNP1 F-RBM7 are shown. (Right) RIP-qPCR of 7SK in HEXIM1 IP. Conditions with WT (red bars), mRNP1 (black bars) and without (blue bars) F-
RBM7 incubation are shown. Results are presented as the mean ± s.e.m. (n = 4 independent experiments). ***, P < 0.001, determined by Student's t
test.
(Figure 3B). Notably, the response to 4-NQO was rather specific
as only 10-13% of mRNAs and uaRNAs, and 3-5% of lincRNAs
and eRNAs underwent expression changes (Table S7). In
accordance with the previous work on transcriptional response to
UV (McKay et al., 2004; Williamson et al., 2017), the up-regulated
coding genes were dramatically shorter than the down-regulated
genes (Figures 3C and S7). Finally, p53, bulky DNA adduct-
inducers camptothecin and cisplatin, as well as DNA-damaging
doxorubicin and sirolimus were identified by Ingenuity Pathway
Analysis (IPA) Upstream Regulator analytic as top regulators that
could yield the 4-NQO-like response at coding genes (Table S8),
suggesting that DNA damage had indeed mediated the
transcriptional changes.
To explore further the role of P-TEFb in the DDR, we
compiled a set of 4-NQO-induced coding genes, which showed
decreased mRNA levels by at least 20 percent upon FP co-
treatment (4FP set; Table S9). IPA identified cell death and
survival, cellular development, cellular growth and proliferation,
gene expression and cell cycle as the most significant cellular
functions controlled by the 551-gene 4FP set (Figure 3D).
Moreover, comparing it with gene sets of the Molecular
Signatures Database (MSigDB) collection revealed that the 4FP
set was enriched for nucleic acid binding proteins controlling
gene expression (p-value=1.4x10-16-4.36x10-33; Table S10),
which likely specify the response. In fact, the 4FP set bears
similarity  to  the  one  controlled  by NF-kB (p-value= 6.01x10-57)
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Figure 3. Active P-TEFb is vital for Pol II transcriptional response to DNA damage.
(A) (Top) Schematic depicting major steps in the generation of 4sU-labeled transcripts (4sU RNA) for 4sU-seq. (Bottom) Pie charts showing the
fractions of DE protein-coding genes (mRNA) upon one and two hours of 4-NQO treatment of HeLa cells as assessed by 4sU-seq (n = 2 independent
experiments).
(B) Bar charts showing the number of DE classes of transcripts in HeLa cells as assessed by 4sU-seq (n = 2 independent experiments). The degrees
of differential expression are presented according to the legend. Conditions with (in hours) and without (-) 4-NQO or FP are shown.
(C) Boxplots indicating the distribution of gene lengths for up-regulated and down-regulated protein-coding genes. Median gene length for each group
is marked in grey and indicated above the boxes.
(D) Top Molecular and Cellular Functions categories of the 4FP gene set as identified by IPA. The number of affected genes per category is shown
on the right.
(E) RT-qPCR of the indicated DNA damage-induced unspliced (pre-mRNA), uaRNA and eRNA transcripts. HeLa cells were treated as indicated by
the legend. Results were normalized to the DMSO control and are presented as the mean ± s.e.m. (n = 3 independent experiments). *, P < 0.05; **,
P < 0.01; ***, P < 0.001, determined by Student's t test.
and of the p53 pathway (p-value=1.23x10-40) (Table S11).
Notably, both transcription factors (TFs) function in DDR (Gomes
et al., 2006; McKay et al., 2004; Sullivan et al., 2018; Wu et al.,
2006) and require P-TEFb for inducing their target genes
(Barboric et al., 2001; Gomes et al., 2006). The 4FP set overlaps
significantly with the UV-induced gene sets of the MSigDB
collection (p-value=3.8x10-50-2.02x10-56; Table S12) and is
predicted by IPA to respond to DNA damage-inducing agents
(Table S13).
We conducted kinetic quantitative RT-PCR (qRT-PCR)
assays using HeLa cells to confirm that nascent transcripts of key
DDR genes of the 4FP set, including oncogenic JUN, FOS and
EGR1 (Lopez-Bergami et al., 2010; Thompson et al., 2009), a
cell cycle inhibitor and a pro-survival CDKN1A/P21 (Besson et
al., 2008; Cazzalini et al., 2010; Chen et al., 2009), an anti-
apoptotic MCL1 (Zhou et al., 1997), and a DDR regulator
GADD45b (Moskalev et al., 2012), are up-regulated in the wake
of DNA damage-induced P-TEFb activation (Figure 3E).
Importantly, co-administration of FP attenuated the induction of
genes (Figure 3E). Similarly, the levels of oncogenic EGR2 pre-
mRNA and its eRNA, as well as those of EXT1, RBM39 and their
corresponding uaRNAs increased with a similar kinetic in a
P-TEFb-dependent manner (Figure 3E). Together, these findings
demonstrate that induced Pol II transcription of short protein-
coding and non-coding genomic loci through P-TEFb is a
hallmark of early DDR.
RBM7 and 7SK snRNP enable induction of P-TEFb-
dependent DDR genes
We next subjected the above protein-coding DDR genes to
detailed mechanistic analyses. To provide further evidence that
they are indeed controlled by P-TEFb upon genotoxic stress, we
monitored the occupancy of CDK9 near transcription start sites
(TSS) of the seven genes by conducting gene-specific
quantitative chromatin immunoprecipitation (ChIP-qPCR) assays
using unchallenged and 4-NQO-treated HeLa cells. Furthermore,
we followed the occupancy of total Pol II and its P-TEFb-
generated Ser2-P form near the TSS and in the middle of gene
interior (INT) of each DDR gene. To take into account the
expected 4-NQO-provoked changes in Pol II occupancy at the
genes, we normalized Ser2-P signals to those of total Pol II. In
accordance with our biochemical and nascent transcript findings,
we observed that 4-NQO exposure elevated occupancy of CDK9
near  the  TSS  of  nearly  all  tested  DDR genes (Figures 4A and
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Figure 4. RBM7 and 7SK snRNP are critical for induction of P-TEFb-dependent DDR genes.
(A) ChIP-qPCR of the occupancy of CDK9 and Ser2-P relative to Pol II at transcription start site (TSS) and in the middle of gene interior (INT) of the
indicated DDR genes. The ChIP-qPCR data at the intergenic site approximately 100 kb upstream of FOS TSS is also presented. Conditions with (red
bars) and without (blue bars) 4-NQO are shown. Results were normalized to the DMSO control and are presented as the mean ± s.e.m. (n = 3
independent experiments). *, P < 0.05; **, P < 0.01, determined by Student's t test. (B) RT-qPCR (left) of unspliced transcripts (pre-mRNA) of the
indicated DDR genes and ChIP-qPCR (right) of the levels of Ser2-P relative to Pol II at transcription start site (TSS) and in the middle of gene interior
(INT) of the indicated DDR genes in control (siCtrl; red) and RBM7 knockdown (siRBM7 #2; yellow) 4-NQO-treated HeLa cells. In RT-qPCR assays,
the cells were exposed to 4-NQO for 15 min, 0.5 hr, 1 hr and 2 hr as indicated, and results were normalized to the untreated control and are presented
as the mean ± s.e.m. (n = 3 independent experiments). *, P < 0.05; **, P < 0.01; ***, P < 0.001, determined by Student's t test. ChIP-qPCR results
were normalized to the control values that were set to 1 and are presented as the mean ± s.e.m. (n = 3 independent experiments). *, P < 0.05; **, P <
0.01, determined by Student's t test.
(C,D) RT-qPCR of unspliced transcripts of the indicated DDR genes in parental, WT and mRNP1 F-RBM7-expressing or 7SK-depleted HeLa cells.
The cells were treated for 2 hr with DMSO or 4-NQO as indicated by the legend. Results were normalized to the respective DMSO control and are
presented as the mean ± s.e.m. (C: n = 4 independent experiments; D: n = 3 independent experiments). *, P < 0.05; **, P < 0.01; ***, P < 0.001,
determined by Student's t test. Levels of the F-RBM7 proteins and efficacy of the RN7SK knockdown with the 7SK antisense DNA oligonucleotide
(as7SK) are shown on the left.
S8A). Concomitantly, levels of the Ser2-P hallmark of productive
Pol II elongation also increased at the sites upon genotoxic
stress, particularly near TSS that correspond to the locations of
paused Pol II (Figures 4A and S8A). Furthermore, FP blocked
the increased Ser2-P levels (Figure S8B). The observed CDK9,
Pol II and Ser2-P Pol II occupancies were specific as they were
enriched significantly over the normal IgG and FOS intergenic
site controls (Figure S8C). These results highlight further the role
of P-TEFb in stimulating Pol II transcription following DNA
damage.
Our findings thus far are consistent with the model in which
following genotoxic stress, RBM7 activates P-TEFb by releasing
it from the core of 7SK snRNP, resulting in transcriptional
stimulation of specific gene sets. According to this scenario,
interfering with RBM7 or its regulatory target, 7SK snRNP, should
hamper the 4-NQO-triggered gene induction. Indeed, by using
kinetic qRT-PCR assays we found that RBM7 knockdown led to
the reduction of 4-NQO-induced levels of nearly all analyzed pro-
survival and DDR gene transcripts in HeLa cells (Figures 4B and
S8D). Importantly, this transcriptional defect coincided with
decreased levels  of  the  Ser2-P  mark  at the induced genes as
revealed by ChIP-qPCR experiments (Figures 4B and S8D),
underscoring  the  importance  of  RBM7 in enabling the  P-TEFb-
dependent gene induction.  In further support of this notion,  we
found that HeLa cells constitutively expressing the 7SK binding-
deficient mRNP1 F-RBM7 exhibited decreased induction of these
genes upon 4-NQO exposure when compared to the parental or
F-RBM7 expressing HeLa cells (Figure 4C), suggesting that
mRNP1 F-RBM7 lowered the transcriptional response by acting
in a dominant-negative fashion. Finally, we used 7SK-specific
phosphorothioate-modified antisense DNA oligodeoxynucleotide
to deplete the scaffolding 7SK, which disintegrates 7SK
snRNP(Yik et al., 2003), and also detected a compromised
transcriptional response to genotoxic stress (Figure 4D).
Together, these results show the vital role of RBM7 in the DNA
damage-induced activation of P-TEFb, which stimulates Pol II
elongation at pro-survival and DDR genes.
P-TEFb and RBM7 promote cell viability upon genotoxic
stress
Given the importance of RBM7 and P-TEFb in facilitating
transcriptional activation following genotoxic stress, we finally
hypothesized that antagonizing the RBM7:P-TEFb axis during
DDR should be detrimental to cell survival. This possibility was
further supported by our analysis of the 4FP set with IPA
Downstream  Effects  Analysis  tool,   which   predicted  that   the
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Figure 5. P-TEFb and RBM7 promote cell viability upon genotoxic stress.
(A,B) Hypersensitivity of HeLa and RPE cells to 4-NQO upon FP treatment and RBM7 depletion. The cells were treated as indicated by the legends
and examined at the time points indicated below the graphs. Two independent siRNAs (siRBM7 #2, HeLa cells; siRBM7 #1, RPE cells) were used to
deplete RBM7. Cytotoxicity results are presented as fluorescence values relative to the untreated control and plotted as the mean ± s.e.m. (n = 3
independent experiments). *, P < 0.05; **, P < 0.01; ***, P < 0.001, determined by Student's t test using 4-NQO and 4-NQO FP or 4-NQO siRBM7
data sets, respectively.
(C,D) FP treatment and RBM7 depletion enhance 4-NQO-induced apoptosis in HeLa cells. The cells were treated as indicated by the legends and
examined at the time points indicated below the graphs. siRBM7 #2 was used to deplete RBM7. Apoptosis results are presented as luminescence
values relative to the untreated control and plotted as the mean ± s.e.m. (n = 3 independent experiments). *, P < 0.05; **, P < 0.01, determined by
Student's t test using 4-NQO and 4-NQO FP or 4-NQO siRBM7 data sets, respectively.
(E) Model of P-TEFb activation by RBM7 during DDR. DNA damage signaling (step 1) provokes phosphorylation (green circle) of RBM7 by the
p38MAPK/MK2 pathway. Subsequently, RBM7 of the trimeric NEXT complex binds 7SK snRNP (step 2) to release the inactive P-TEFb (CDK9 in red)
from the core of 7SK snRNP (step 3), yielding active P-TEFb (CDK9 in green). In turn, transcription factors (TF) capture P-TEFb on chromatin (step
4). Stimulation of pro-survival DDR gene transcription at the Pol II pause release phase ensues (step 5), which is achieved by P-TEFb-mediated
phosphorylation (green circles) of Pol II CTD at Ser2 as well as the negative transcription elongation factors (N-TEFs) NELF and DSIF. While NELF
dissociates from Pol II, DSIF becomes a positive transcription elongation factor.
genotoxic  stress-induced  genes  under  P-TEFb control promote
cellular viability (Table S14). Thus, we performed time course
cytotoxicity assays in which compromised membrane integrity of
dead cells is proportional to fluorescence signal generated by the
binding of an otherwise cell impermeable cyanine dye to DNA.
For these experiments, we used HeLa cells, a cell line derived
from the retinal pigment epithelium (RPE), and primary HFF-1
cells. Of note, UV-induced stress leads to death or dysfunction of
RPE cells, which is thought to underlie several retinal diseases,
including central vision loss of the age-related macular
degeneration (Roduit and Schorderet, 2008). Confirming our
hypothesis, we found that HeLa, RPE and HFF-1 cells became
hypersensitive to 4-NQO when treated with the concentration of
FP that attenuated the induction of P-TEFb-dependent target
genes, reaching death of nearly all cells at 36 and 72 hours,
respectively (Figures 5A and S9A). Depletion of RBM7 by two
different siRNAs resulted in a similar hypersensitivity of HeLa and
RPE cell lines to 4-NQO and UV (Figures 5B, S9B, and S9C). Of
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note, ectopically expressed F-RBM7, which was resistant to the
siRNA-mediated repression targeting the 3’ untranslated region
of the endogenous RBM7 transcripts, increased survival of
4-NQO-treated HeLa cells (Figure S9D). This provides further
support that our RNAi findings were specific. We also conducted
viability assays to provide additional evidence for the critical role
of P-TEFb and RBM7 in the survival of genotoxic-stressed HeLa
cells. We employed a fluorescence-based assay in which the
indicator compound resazurin is reduced upon entering cells due
to the reducing power of living cell cytosol, resulting in its
fluorescence capacity. Corroborating our cytotoxicity results,
P-TEFb inhibition and RBM7 depletion decreased the viability of
4-NQO-exposed HeLa cells (Figures S9E and S9F).
Finally, we asked if apoptosis was responsible for the
hypersensitivity of P-TEFb or RBM7 deficient cells to genotoxic
stress. Thus, we subjected HeLa cells to the same conditions as
in the above functional experiments. We followed kinetics of
apoptosis using a luminescence-based assay that measures the
exposure of phosphatidylserine on the outer cell membrane
surface during apoptosis with two Annexin V fusion proteins
containing fragments of NanoBit Luciferase (Dixon et al., 2016),
of which complementation is achieved through Annexin V -
phosphatidylserine binding. Indeed, FP treatment and RBM7
depletion enhanced 4-NQO-stimulated apoptosis (Figures 5C
and 5D). Comparison of the cytotoxicity and apoptosis kinetics
shows that the onset of apoptosis precedes the occurrence of cell
death, indicating that apoptosis was causing the cellular demise.
As an independent measure of apoptosis activation, we also
monitored cleavage of poly(ADP-ribose) polymerase (PARP) and
Caspase-3 by Western blotting. Supporting our kinetic results,
we also found that inhibiting P-TEFb activation in 4-NQO-treated
HeLa cells with FP and RBM7 depletion enhanced the levels of
PARP and Caspase-3 cleavage products (Figures S9G and
S9H). Together, these findings show the critical importance of the
RBM7:P-TEFb axis in enabling a pro-survival transcriptional
response to genotoxic stress.
DISCUSSION
Reshaping cellular gene expression program in the face of
external or internal stress is a fundamental characteristic of all
living forms. In this study, we investigated the mechanisms and
importance of transcriptional activation following genotoxic
stress. We uncovered that stimulation of Pol II pause release by
P-TEFb is at the heart of cellular DDR (Figure 5E). We identified
RBM7 of the trimeric NEXT complex as a critical regulator
directing the DNA damage-induced release of P-TEFb from the
core of 7SK snRNP, which in turn enables a concerted
transcriptional response that is indispensable to the survival of
stressed cells. We envision that upon activation of P-TEFb, its
recruiting factors including Brd4, the Mediator and transcriptional
activators (Quaresma et al., 2016; Takahashi et al., 2011; Yang
et al., 2005), especially those playing critical roles in DDR such
as NF-kB and p53 (Barboric et al., 2001; Gomes et al., 2006;
McKay et al., 2004; Wu et al., 2006), capture the kinase on
chromatin, thereby underwriting specificity to the transcriptional
outcome and resolution to the genotoxic affront.
Our work provides a novel paradigm in stress-dependent
control of Pol II pause release. The exosome-independent role of
RBM7 in the activation of P-TEFb expands our knowledge of its
regulatory ability, which has been thus far limited to enabling
RNA degradation (Lubas et al., 2015). Considering that UV
irradiation impairs the RBM7-mediated ribonucleolysis by
triggering its phosphorylation via the p38MAPK/MK2 pathway
(Blasius et al., 2014; Tiedje et al., 2015), genotoxic stress thus
switches a function of RBM7 from facilitating RNA degradation to
promoting DNA transcription. Of note, RBM7 binds near-
stoichiometric levels of hMTR4 and ZCCHC8 in cell extracts
(Andersen et al., 2013; Lubas et al., 2011), indicating its primary
engagement within NEXT. Therefore, despite the capacity of
purified RBM7 to release P-TEFb from 7SK snRNP in vitro, it is
likely that RBM7 accomplishes this task in vivo as a subunit of
NEXT. This possibility could explain the observed dominant-
negative effect of the 7SK binding-deficient mRNP1 F-RBM7 on
the induction of DDR genes, where the mutant protein might
interfere with the function of endogenous RBM7 by dislodging it
from NEXT. We speculate that P-TEFb activation is not limited to
DDR. It might take place also in response to other types of stress,
such as hypoxic milieu of tumor cells, in which the oncogenic
transcriptional activator HIF1A could co-opt increased availability
of active P-TEFb for alleviating Pol II pausing at hypoxia-
inducible genes (Galbraith et al., 2013).
Importantly, this study clarifies our understanding of the
significance of stimulating Pol II transcription upon DNA damage.
Since P-TEFb targets promoter-proximal Pol II that is poised for
productive elongation, its stress-induced activation and
chromatin recruitment is suited uniquely to promote the rapid and
coordinated transcriptional response. Our 4sU-seq and ChIP-
qPCR findings are in agreement with recent studies reporting
increased levels of nascent RNA synthesis at promoter-proximal
regions following UV irradiation (Andrade-Lima et al., 2015;
Lavigne et al., 2017; Williamson et al., 2017). It remains to be
established, however, how exactly does the stimulation of Pol II
pause release via RBM7 and P-TEFb promote survival of cells
experiencing genotoxic stress. We propose that transcriptional
reprogramming plays a pivotal role. While induction of coding
DDR genes as exemplified by CDKN1A/P21 and MCL1, as well
as lincRNAs enables cell cycle arrest and opposes apoptosis
(Cazzalini et al., 2010; Huarte et al., 2010; Hung et al., 2011;
Zhou et al., 1997), elevated levels of eRNAs and uaRNAs might
concurrently stabilize new gene expression program through
various mechanisms, which could include local modulation of
chromatin environment (Bose et al., 2017; Lai et al., 2013;
Mousavi et al., 2013), facilitation of TFs occupancy (Sigova et al.,
2015), and augmentation of Pol II pause release (Schaukowitch
et al., 2014). Accordingly, we speculate that the transiently
reshaped transcriptome sets the stage for subsequent recovery
from genotoxic stress. Therein activation of P-TEFb could be also
advantageous to the repair of damaged DNA itself. Supporting
this premise, stimulating the release of Pol II from promoter-
proximal pausing could enhance detection of DNA damage
throughout the transcribed genome, resulting in more effective
transcription-coupled NER (TC-NER) (Andrade-Lima et al., 2015;
Chiou et al., 2017; Lavigne et al., 2017). Namely, Pol II stalled at
the sites of DNA damage mediates activation of this pathway
(Hanawalt and Spivak, 2008; Vermeulen and Fousteri, 2013),
and because Pol II dissociates from DNA during individual TC-
NER reactions (Chiou et al., 2017), the repair of following DNA
lesions would benefit from successive rounds of Pol II pause
release events. In addition, active P-TEFb might exert its positive
role via its DNA damage-induced interaction with Cockayne
syndrome B translocase (Boeing et al., 2016), which is
instrumental for TC-NER and resetting of Pol II transcription as
cells recover from DNA damage (Epanchintsev et al., 2017;
Mayne and Lehmann, 1982).
Finally, P-TEFb-dependent Pol II pause release is frequently
dysregulated in cancers, particularly in those addicted to c-MYC
and translocations of mixed-lineage leukemia gene (Dawson et
al., 2011; Delmore et al., 2011; Huang et al., 2014; Ji et al., 2014;
Luo et al., 2012; Rahl et al., 2010; Tan et al.), spurring interest in
the development of highly specific CDK9 inhibitors for clinical use
(Lu et al., 2015; Olson et al., 2018). Our discovery of the pro-
survival role of P-TEFb in genotoxic stress reinforces the
relevance of this critical transcriptional kinase to cancer biology.
Hence, our work offers a framework for novel anti-cancer
approaches with targeting RBM7 and P-TEFb in addition to DNA-
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damaging chemotherapeutics. Countering the RBM7:P-TEFb
axis might prove especially effectual in combination with broad
spectrum bulky DNA adduct-inducing platinum-based drugs such
as cisplatin, which shows improved therapeutic outcome in NER-
deficient cancers (Dietlein et al., 2014; Gavande et al., 2016).
The proposed combinatorial approach might also curb the
emergence of drug-resistant tumor cells (Sharma et al., 2010;
Shen et al., 2012; Yashiro-Ohtani et al., 2014), a major challenge
of contemporary cancer monotherapies.
EXPERIMENTAL PROCEDURES
Cell Culture
HEK 293, HEK 293 Flp-In T-REx (Thermo Fisher Scientific), HeLa
(ATCC), HeLa Flp-In and human foreskin fibroblast (HFF-1, ATCC) cell
lines were grown in Dulbecco‘s Modified Eagle‘s Medium (D-MEM;
Sigma, D5796) supplemented with 10% fetal bovine serum (FBS) and
100 U/ml penicillin/streptomycin. The parental HEK 293 Flp-In T-REx and
HeLa Flp-In cell lines were grown with 50mg/ml of zeocin (InVivogen, ant-
zn-1). HEK 293 Flp-In T-REx cell lines expressing 3X-FLAG peptide or
3X-FLAG epitope-tagged proteins were generated according to the
manufacturer’s instructions  and grown with 100 mg/ml of Hygromycin B
Gold (InVivogen, ant-hg-5) and 3 mg/ml of Blasticidin (InVivogen, ant-bl-
1). HeLa Flp-In F-CBP20 cell line was grown with 200 mg/ml of
Hygromycin B Gold. Both HeLa Flp-In cell lines were a gift from Dr.
Bertrand and described previously (Hallais et al., 2013). Retinal pigment
epithelium (RPE) cell line (ATCC) was grown in D-MEM/F12 (Sigma,
D8437) supplemented with 10 % fetal bovine serum (FBS) and 100 U/ml
penicillin/streptomycin. Cell lines were maintained at 37 oC with 5 % CO2.
Cell lines used in this study are listed in Supplementary Table 15.
Plasmid DNAs and Mutagenesis
To generate plasmid DNAs encoding 3X-FLAG epitope-tagged HEXIM1,
LARP7, CDK9 and RBM7, the cDNAs were amplified using Phusion DNA
polymerase (NEB, M0530) with primers carrying the appropriate
restriction enzymes sites and cloned using Rapid Ligation Kit (Thermo
Fisher Scientific, K1423) into pcDNA5/FRT/TO
(https://www.addgene.org/vector-database/2133/) vector, which was
modified to encode 3X-FLAG peptide upstream of the multiple cloning
site (a gift from Dr. Ule). To generate plasmids encoding the mutant
RBM7 proteins, pcDNA5/FRT/TO/3X-FLAG-RBM7 was used for
mutagenesis with Q5® Site-Directed Mutagenesis Kit (NEB, E0554S). To
generate pcDNA5/FRT/TO/3X-FLAG-RBM7 mRNP1, the primer
sequences used were: 5’-TGCGGCTGTGAATTTCAAACATGAAGTG-3’;
5’-GCCTGCGCTGGTTTACCATCCTTATCTTTTG-3’. To generate
pcDNA5/FRT/TO/3X-FLAG-RBM7 S136A, the primer sequences used
were: 5’-GCTTCTCCAGAAAATTTTCAGAGACAAG-3’; 5’-
GAAAGATCTCTGAATTATCTGTGCTG-3’.  Plasmids used in this study
are listed in Supplementary Table 16.
Chemicals and Treatments
4-Nitroquinoline N-oxide (4-NQO; Sigma, N8141) was diluted in DMSO
to a final concentration of 50mM, aliquoted, sealed and stored at -80 oC.
UV irradiation was performed in Crosslinker CL-1000 using 254 nm
wavelength lamp with dose 40-60 J/m2. Flavopiridol (Sigma, F3055) and
4sU (Sigma, T4509) were diluted in DMSO to a final concentration of 1
mM and stored at -20 oC. Tetracycline hydrochloride (Sigma, T7660) was
diluted in water to a final concentration of 1mg/ml, aliquoted and stored
at -20 oC.
RBM7 iCLIP Assay
HEK 293 Flp-In T-REx F-RBM7 cells were treated for 24 hours with 2
μg/ml of doxycycline to express F-RBM7, exposed for 2 hours to DMSO
or 5 mM of 4-NQO, washed once with PBS and UV-cross-linked at 0,15
mJ/cm2 with 254 nm wavelength. Retrieval of protein-bound RNAs and
preparation of cDNA libraries were prepared as described previously
(Huppertz et al., 2014). Cross-linked nucleotides were defined as the
nucleotide upstream of mapped iCLIP cDNA tags as described previously
(Konig et al., 2010). Replicate iCLIP experiments were performed, cross-
linking positions compared between samples, and the replicates were
subsequently combined into groups for final analysis using the iCount
package (http://icount.biolab.si/).
Quantitative RNA Immunoprecipitation Assay
HEK 293 Flp-In T-REx cells grown on 15 cm plates were treated for 16
hours with 1 mg/ml of tetracycline to express the 3X-FLAG epitope-tagged
proteins and exposed at approximately 90 % confluency to DMSO or 10
mM of 4-NQO for 2 hours. The cells were resuspended in Falcon tubes
with 10 ml of ice-cold PBS and cross-linked with 1% formaldehyde at
room temperature for 10 minutes, which was stopped with 250 mM of
glycine for 5 minutes. The cells were then washed twice with ice-cold
PBS, resuspended in buffer A (5 mM PIPES, 85 mM KCL, 0.5 % NP-40,
pH 7.9), and incubated 10 minutes on ice for nuclear extraction. Nuclear
pellets obtained by centrifugation were lysed in 1 ml of RIPA buffer (50
mM Tris pH 8.0, 150 mM NaCL, 5 mM EDTA pH 8.0, 0.5 % sodium
deoxycholate, 1 % NP-40, 0.1 % SDS) in the presence of EDTA-free
Protease Inhibitor Cocktail (Sigma, 11873580001) and SUPERase In
RNase Inhibitor (Thermo Fisher Scientific, AM2694). The lysates were
then sonicated during one round of 35 cycles of 30 sec ON/30 sec OFF
at  4 oC with the Bioruptor Plus sonication device (Diagenode,
B01020001) combined with the Bioruptor Water cooler (Cat. No. BioAcc-
cool) & Single Cycle Valve (Cat. No. VB-100-0001) at high power setting
(position H) using 1.5 ml TPX microtubes (Cat. No. M-50001). After
centrifugation at 13 000 g for 15 min, 5 % of supernatant was stored at -
80 oC for determining RNA input. The rest of the sample was divided in
three equal parts, which were supplemented with additional 600 μl of
RIPA buffer and incubated overnight at 4 oC with 15 ml of antibody-
coupled protein G Dynabeads (Thermo Fisher Scientific, 10004D).
Before adding the supernatant, the beads were pre-blocked with bovine
serum albumin and salmon sperm DNA overnight at a final concentration
of 0.2 mg/ml, pre-incubated in 500 μl of RIPA buffer for 4 hours with the
antibody and collected by magnetic stand to remove the unbound
antibody. We used 3 mg of normal mouse IgG (Santa Cruz Biotechnology,
sc-2025), 3 mg of anti-FLAG (Sigma, F1804), or 3 mg of anti-HEXIM1
(Everest Biotech, EB06964) antibody. The beads were then washed with
RIPA high salt buffer (20 mM Tris pH 8.0, 500 mM NaCL, 2 mM EDTA
pH 8.0, 1 % Triton-X, 0.1 % SDS), RIPA low salt buffer (20 mM Tris pH
8.0, 150 mM NaCL, 2 mM EDTA pH 8.0, 1 % Triton-X, 0.1 % SDS), LiCl
wash buffer (250 mM LiCl, 1 % NP-40, 1 % sodium deoxycholate) and
TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0). RNA-protein complexes
were eluted at room temperature with elution buffer (1 % SDS, 100 mM
NaHCO3). After reverse the cross-linking, RNAs from eluates and inputs
were isolated using TRIzol LS reagent (Thermo Fisher Scientific,
10296028) according to the manufacturer’s protocol. RNA samples were
DNase-treated with the Turbo DNA-Free kit (Ambion, AM1907), reverse
transcribed with SuperScript III reverse transcriptase (Thermo Fisher
Sceintific, 18080044) and random hexamers (Thermo Fisher Scientific,
N8080127), and amplified using FastStart Universal SYBR Green QPCR
Master (Rox) (Roche, 04913914001), RNA-specific primer pair, and
Stratagene Mx3005 qPCR machine. Primers were from Integrated DNA
Technologies and designed using PrimerQuest Tool. Values were
normalized to their levels in RNA inputs and calculated using the MxPro
QPCR Software. Results from at least three independent experiments
are presented as the mean ± s.e.m. Sequences of the primers used in
RIP-qPCR assays are listed in Supplementary Table 17.
Co-immunoprecipitation and Western Blotting Assays
HEK 293 Flp-In T-REx cells grown on 10 cm plates were treated for 16
hours with 1 μg/ml of tetracycline to express the 3X-FLAG epitope-tagged
proteins and exposed to DMSO or 10 mM of 4-NQO for 2 hours. Whole
cell extracts (WCE) were prepared by lysing the cell pellets on ice for 15
min with buffer C (20 mM Tris-HCl, 0.5 % NP-40, 150 mM NaCl, 1.5 mM
MgCl2, 10 mM KCl, 10 % Glycerol, 0.5 mM EDTA, pH 7.9) in the presence
of protease cocktail inhibitor (Thermo Fisher Scientific, 88266), followed
by 10 seconds sonication with the Misonix XL-2000 Ultrasonic Liquid
Processor using the P-1 Microprobe 3.2 mm tip, power setting 3, and
centrifugation of lysates at 20 000 g for 15 min.  For FLAG
immunoprecipitation, WCE were incubated at 4 oC for 4 hours with buffer
C-equilibrated anti-FLAG M2 affinity gel (Sigma, A2220), immuno-
complexes were washed three times with buffer C, eluted in SDS running
buffer in the presence of dithiothreitol (DTT-RO, Sigma) for 5 min at 95
oC and resolved using 12% SDS-PAGE. For total Pol II co-
immunoprecipitation (co-IP), 1 mg of the anti-Pol II 8WG16 antibody
(Abcam Biotech, ab817) was immobilized on Protein G Dynabeads
(Thermo Fisher Scientific, 10004D) according to manufacturer’s
instructions. WCE were prepared using ELB buffer (50 mM HEPES-KOH
pH 7.9, 0.1% Triton X-100, 5 mM dithiothreitol, 5 mM EDTA, 150 mM
NaCl), incubated with the ELB buffer-equilibrated beads for 16 hours at 4
oC, and the beads were washed three times ELB buffer. For endogenous
HEXIM1  co-IP,  2 mg of the anti-HEXIM1 antibody (Everest Biotech,
EB06964) was immobilized on Protein G Dynabeads (Thermo Fisher
Scientific, 10004D) according to manufacturer’s instructions. In the case
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of HEXIM1 co-IP using HEK 293 Flp-In T-REx F-RBM7 and HEK 293 Flp-
In T-REx F-RBM7 mRNP1 cell lines, the cells were treated for 24 hours
with 1 μg/ml of tetracycline to express the 3X-FLAG epitope-tagged
proteins. Upon cell lysis in buffer C, WCE were then added to the buffer
C-equilibrated beads and incubated for 16 hours at 4 oC, and the beads
were washed three times with buffer C. 50 % of the beads was used to
determine the levels of HEXIM1, CDK9 and F-RBM7 by Western blotting.
To determine the levels of 7SK in anti-HEXIM1 co-IP, 500 ml of TRI
reagent (Sigma, T9424) was added to the remaining 50 % of the beads
for RNA extraction. RNA samples were DNase-treated with the Turbo
DNA-Free kit (Ambion, AM1907), reverse transcribed with SuperScript III
reverse transcriptase (Thermo Fisher Sceintific, 18080044) and random
hexamers (Thermo Fisher Scientific, N8080127), and quantified with the
Stratagene Mx3005 qPCR machine as described above using 5S rRNA
as a normalizing control. Results from independent experiments are
presented as the mean ± s.e.m. For Western blotting, the following
antibodies were used according to manufacturers’ instructions: anti-
FLAG (Sigma, F3165); anti-RBM7 (Sigma, HPA013993; Proteintech,
21896-1-AP); anti-HEXIM1 (Everest Biotech, EB06964); anti-CDK9
(Santa Cruz Biotechnology, sc-484); anti-LARP7 (a gift from Dr. Qiang
Zhou described previously(He et al., 2008)); anti-MePCE (Santa Cruz
Biotechnology, sc-82542); anti-RNA polymerase II CTD repeat
YSPTSPS (phospho S2) antibody (Abcam, ab5095); anti-hnRNP A1
(Abnova, MAB2492); anti-g-H2AX (Abcam, ab22551); anti-
hMTR4/SKIV2L2 (Abcam, ab70551); anti-EXOSC3 (Santa Cruz
Biotechnology, sc-166568); anti-cyclin T1 (Santa Cruz Biotechnology, sc-
10750), anti-Cleaved PARP (Cell Signaling Technology, 9541); anti-
Cleaved Caspase-3 (Cell Signaling Technology, 9661). Manufacturers
provide validation for all antibodies.
Immunofluorescence Microscopy
HeLa cells were grown on polylysine coated coverslips, treated with
DMSO or 10 μM of 4-NQO for 1 hour, washed twice in PBS, and
incubated in cytoskeletal buffer (CSK; 10 mM Pipes pH 6.8, 300 mM
sucrose, 100 mM NaCl, 3 mM MgCl2, 1 mM EGTA) for 10 min. Cells were
then fixed in 4% formaldehyde in CSK buffer for 1 hour on ice and blocked
with TBS-I (10 mM Tris pH 7.7, 150 mM NaCl, 3 mM KCl, 1.5 mM MgCl2,
0.05%  Tween 20, 0.1% BSA, 0.2% glycine) for at least 1 hour on ice.
Primary antibody staining using anti-gH2AX (Abcam, ab22551; 1:100
dilution) was done overnight at 4 oC, which was followed by two washes
with ice cold CSK buffer. Secondary antibody staining using goat anti-
mouse conjugated with AlexaFluor 488 (Thermo Fisher Scientific,
A11001; 1:1000 dilution) was performed for 4 h at 4 oC. Cells were then
washed twice with ice cold CSK buffer, incubated with NucBlue reagent
(R37606, Thermo Fisher Scientific) for 30 min at room temperature and
washed three times with ice cold CSK buffer. Coverslips were mounted
with ProLong Gold Antifade Mountant (Thermo Fisher Scientific,
P10144). Images were acquired by AxioLab microscope equipped with
AxioCam and AxioVision 4.3 software (Zeiss), and analyzed using
CorelDRAW Graphic Suite 2017. Representative images show cells
treated with DMSO or 250 nM of 4-NQO for 1 hour. The number of cells
with at least one nuclear γ-H2AX foci from two independent experiments
was counted, plotted as percentage of the total number of cells in the
field, and presented as the mean ± s.e.m. For each independent
treatment, cells were counted from at least ten fields containing at least
ten cells per field.
Glycerol Gradient Sedimentation Analysis
HeLa Flp-In cells were treated with DMSO or 10 μM of 4-NQO for 2 hours,
lysed on ice for 15 min in 0.6 ml of lysis buffer B (20 mM HEPES, 0.3 M
KCl, 0.2 mM EDTA, 0.1 % NP-40, 0.1 % protease inhibitor, pH 7.9).
Cellular extracts were then subjected to ultracentrifugation in a SW41 Ti
rotor (Beckman) at 38 000 rpm for 16 hours in a 10 ml glycerol gradient
solution (10–30 %) containing buffer B. Fractions were collected and
analyzed as described previously (Yik et al., 2005).
Bimolecular Fluorescence Complementation Assay
HeLa Flp-In cells grown on 6-well plates were co-transfected with 0.2 mg
of pEF.YN-CTD and 2 mg of pEF.YC-P-TEFb plasmids using X-
tremeGENE transfection reagent (Sigma, XTG9-RO). Twenty-four hours
after transfection, the cells were seeded into 6-8 wells of a 24-well plate
and grown an additional 24 to 48 hours. The cells were then left untreated
or treated with DMSO, with 2, 5, and 10 μM of 4-NQO for 0.5, 1, and 4
hours, and with 5 μM of SAHA or JQ1 for 1 hour. Fluorescence signals
were detected using Olympus IX70 fluorescent microscope. The
fluorescence images were analyzed using MetaMorph software. YFP
positive cells were counted manually and averaged from three randomly
chosen fields of each sample.
P-TEFb Release Assay
P-TEFb release assay was performed as described previously (Calo et
al., 2015) with the following modifications. WCE from one confluent 15
cm plate of HeLa cells was prepared by lysing the cell pellets on ice for
30 min with 1.2 ml of buffer C in the presence of protease cocktail inhibitor
(Thermo Fisher Scientific, 88266). To immobilize 7SK snRNP, 1 ml of
WCE was incubated at 4 oC for 4 hours with 75 ml of Protein G Dynabeads
(Thermo Fisher Scientific, 10004D) that were pre-bound with 5 mg of anti-
HEXIM1 antibody (Everest Biotech, EB06864). For the control, the
remaining 200 ml of WCE was incubated with 15 ml of Protein G
Dynabeads (Thermo Fisher Scientific, 10004D) that were pre-bound with
1 mg of normal IgG antibody. Immuno-purified F-RBM7 proteins were
incubated with the equal amounts of immobilized 7SK snRNP for 2 hours
on ice, which was followed by the collection of samples for Western
blotting analysis from 50 % of the beads. To determine the levels of 7SK
that remained bound to HEXIM1, 500 ml of TRI reagent (Sigma, T9424)
was added to the remaining 50 % of the beads for RNA extraction. RNA
samples were DNase-treated with the Turbo DNA-Free kit (Ambion,
AM1907), reverse transcribed with SuperScript III reverse transcriptase
(Thermo Fisher Sceintific, 18080044) and random hexamers (Thermo
Fisher Scientific, N8080127), and quantified with the Stratagene Mx3005
qPCR machine as described above using 5S rRNA as a normalizing
control. Results from independent experiments are presented as the
mean ± s.e.m. For purification of the 3X-FLAG epitope-tagged RBM7
proteins, the corresponding HEK 293 Flp-In T-REx F-RBM7 cells grown
on three 15 cm plates were treated for 16 hours with 1 mg/ml of
tetracycline to express the F-RBM7 proteins. The cells were lysed in
buffer C. WCE were then incubated with 30 ml of buffer C-equilibrated
anti-FLAG M2 affinity gel (Sigma, A2220) for 16 hours in the presence of
protease inhibitor (Thermo Fisher Scientific, 88665) and RNase A
(Thermo Fisher Scientific, 12091021). After incubation, samples were
washed three times with buffer C, where the first two washes contained
600 mM of NaCl. F-RBM7 proteins were eluted with 300 mg/ml of 3X-
FLAG peptide (ApexBio Technology, A6001) in 50 ml of buffer C, and 10
ml (+) or 20 ml (++) of the eluates were used per each reaction. To
examine their purity, 10 ml eluate samples were subjected to SDS-PAGE
and Western blotting using anti-hMTR4, anti-EXOSC3, and anti-CDK9
antibodies.
4sU-sequencing Assay
Metabolic labeling and isolation of newly transcribed RNA was performed
as described previously (Radle et al., 2013). In brief, 80 % confluent Hela
Flp-In cells were mock-treated or treated with DMSO, 5 mM of 4-NQO, or
5 mM of 4-NQO and 250 nM of flavopiridol for 1 or 2 hours before lysis.
Thirty minutes prior to lysis, the cells were labeled with 4sU at a final cell
culture medium concentration of 100mM. RNA was extracted with TRIzol
reagent (Thermo Fisher Scientific, 15596018) and 150 mg of total RNA
was used for biotinylation with EZ-Link Biotin-HPDP (Thermo Fisher
Scientific, 21341) for 90 minutes at room temperature. Second round of
RNA extraction was performed with chloroform-isopropanol. µMACS
Streptavidin Kit (Miltenyi, #130-074-101) was used for separation of
labeled RNA, which was followed by elution with DTT and RNA extraction
with isopropanol. Libraries from two biological replicates were prepared
and sequenced by Beijing Genomics.
Analysis of 4sU-sequencing Data Sets
Sequencing quality was assessed with FastQC
(http://www.bioinformatics.babraham.ac.uk/ projects/fastqc/) and
sequencing adapters were trimmed using Cutadapt (Martin, 2011).
Reads were mapped against the human reference genome
(GRCh38/hg38) and rRNA sequences using ContextMap 2 (Bonfert et
al., 2015). Read counts for mRNAs, lincRNAs, uaRNAs and eRNAs were
calculated using featureCounts (Liao et al., 2014). mRNA and lincRNA
annotation were taken from Gencode version 25 and eRNA annotations
were taken from the study by Lubas et al. (Lubas et al., 2015). eRNAs
within 5 kb of an annotated gene (according to Gencode) were excluded.
uaRNAs were defined as the window from -3kb to the transcription start
sites of mRNAs and lincRNAs on the opposite DNA strand. If according
to the Gencode annotation another gene was present within 10 kb
upstream of the uaRNA-associated gene, we excluded those uaRNAs
from our analysis. Expression of mRNAs, lincRNAs, uaRNAs and eRNAs
was quantified in terms of fragments per kilobase of exons per million
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mapped reads (FPKM) and averaged between replicates. Differential
gene expression analysis to determine fold-changes in gene expression
and significance of changes was performed using edgeR (Robinson et
al., 2010). Here, only RNAs with an average read count ≥1 in the
respective samples were included. EdgeR models read counts using the
negative binomial distributions and uses the quantile-adjusted conditional
maximum likelihood method to estimate log fold-changes and p-values
for differential gene expression. P-values obtained from edgeR were
corrected by multiple testing using the method by Benjamini and
Hochberg (Benjamini and Hochberg, 1995) for adjusting the false
discovery rate (FDR) and a p-value cutoff of 0.01 was applied. For
correlation analysis, Spearman rank correlation was used. Gene lengths
were obtained from Gencode annotations. Supplementary tables 3–6
contain mRNAs, lincRNAs, uaRNAs and eRNAs which were differentially
expressed upon 1 and 2 hours of 4-NQO treatment. A transcript was
considered consistently regulated if (i) the FDR-adjusted p-value was ≤
0.01 in at least one of the two experimental conditions, (ii) it was regulated
in the same way (either up or down) in both experimental conditions and
(iii) it was not differentially expressed in the DMSO control condition.
Ingenuity Pathway Analysis and Molecular Signature Database
Analysis
The set of protein-coding genes that are differentially expressed upon 1
and 2 hours of 4-NQO exposure and the 4FP gene set were subjected to
IPA Upstream Regulator Analysis, which identifies upstream regulators
that can explain the observed gene expression changes in a user's
dataset. The 4FP gene set was also subjected to IPA Downstream
Effects analytic, which identifies biological functions that are expected to
be increased or decreased given the observed gene expression changes





s_analysis_whitepaper.pdf. Overlaps between the 4FP gene set and
gene sets of the Molecular Signatures Database (MSigDB) collection v6.0
were computed using the on-line tool at
http://software.broadinstitute.org/gsea/msigdb/ index.jsp. Gene set
enrichment analysis, GSEA software, and MSigDB were described
previously (Subramanian et al., 2005).
RNA extraction and RT-qPCR Analysis
Eighty % confluent Hela Flp-In cells grown on 6-well plates were left
untreated or treated with DMSO, 5 mM of 4-NQO, or 5 mM of 4-NQO and
250 nM of flavopiridol for 15 min, 30 min, 1 hour and 2 hours. RNA
samples were extracted using TRI Reagent (Sigma, T9424), DNase-
treated with the Turbo DNA-Free kit (Ambion, AM1907), and reverse
transcribed with M-MLV reverse transcriptase (Thermo Fisher Scientific,
28025-013) and random hexamers (Thermo Fisher Scientific, N8080127)
according to the manufacturers’ instructions. qPCR reactions were
performed with diluted cDNAs, primer pairs that spanned exon-intron
junction, and FastStart Universal SYBR Green QPCR Master (Rox)
(Roche, 04913914001) using Stratagene Mx3005 qPCR machine.
Primers were from Integrated DNA Technologies and designed using
PrimerQuest Tool. Relative levels of transcripts were calculated using the
MxPro QPCR Software v4.10. For 7SK, 7SK DNA value was used as a
normalizer. For other RNAs, GAPDH mRNA  values  were  used  as  a
normalizer. Results from at least three independent experiments are
presented as the mean ± s.e.m. Sequences of the primers used in RT-
qPCR assays are listed in Supplementary Table 18.
Quantitative Chromatin Immunoprecipitation Assay
ChIP-qPCR assay was performed as described previously (Ekumi et al.,
2015) with the following modifications. HeLa Flp-In cells grown on 15 cm
plates were treated at approximately 90 % confluency with DMSO or 5
μM of 4-NQO for 2 hours. For the total Pol II and Ser2-P Pol II assays,
the formaldehyde cross-linked cell pellets were lysed in 800 ml of RIPA
buffer (50 mM Tris pH 8.0, 150 mM NaCL, 5 mM EDTA pH 8.0, 0.5 %
sodium deoxycholate, 1 % NP-40, 0.1 % SDS) in the presence of EDTA-
free Protease Inhibitor Cocktail (Sigma, 11873580001) and SUPERase
In RNase Inhibitor (Thermo Fisher Scientific, AM2694). Lysates were
then sonicated during one round of 35 cycles of 30 sec ON/30 sec OFF
at  4 oC with the Bioruptor Plus sonication device (Diagenode,
B01020001) combined with the Bioruptor Water cooler (Cat. No. BioAcc-
cool) & Single Cycle Valve (Cat. No. VB-100-0001) at high power setting
(position H) using 1.5 ml TPX microtubes (Cat. No. M-50001). After
centrifugation at 13 000 g for 15 min, 2.5 % of the cleared chromatin was
stored at -80 oC for determining DNA input. The rest of the sample was
divided in three equal parts, which were supplemented with additional
600 μl of RIPA buffer and incubated overnight at 4 oC with 14 ml of
antibody-coupled protein G Dynabeads (Thermo Fisher Scientific,
10004D). Before adding the cleared chromatin, the beads were pre-
blocked with bovine serum albumin and salmon sperm DNA overnight at
a final concentration of 0.2 mg/ml, pre-incubated in 500 μl of RIPA buffer
for 4 hours with the antibody and collected by magnetic stand to remove
the unbound antibody. We used 2 mg of anti-RNA polymerase II RPB1
(Abcam, ab76123), 1 mg of anti-RNA polymerase II CTD repeat
YSPTSPS (phospho S2) (Abcam, ab5095), and 3 mg of anti-CDK9 (Cell
Signaling Technology, 2316S) antibodies. Additionally, 2 mg of normal
mouse IgG (Santa Cruz Biotechnology, sc-2025) and normal rabbit IgG
(Santa Cruz Biotechnology, sc-2027) antibodies were used to determine
specificity of the signals. Validation for all antibodies is provided on the
manufacturers' websites. For the CDK9 assays, the cells were cross-
linked using ChIP Cross-link Gold reagent (Diagenode, C01019027) and
formaldehyde according to manufacturer's instructions and lysed as
above. Lysates were sonicated during 30 cycles of 15 seconds sonication
with the Misonix XL-2000 Ultrasonic Liquid Processor using the P-1
Microprobe 3.2 mm tip, power setting 6, in 1.7 ml RNase/DNase-free
microcentrifuge tubes (Sigma, CLS3620), which were kept for 1 min on
ice between the cycles. Generally, 1/60th of the precipitated ChIP sample
was used for each qPCR reaction. For input DNA, 1/100th of the DNA
input dissolved in 100 ml of water was used for each qPCR reaction.
Samples were amplified using FastStart Universal SYBR Green QPCR
Master (Rox) (Sigma, 04913914001), DNA-specific primer pair, and
LightCycler 480 II (Roche) machine. Primers were from Integrated DNA
Technologies and designed using PrimerQuest Tool. Values were
normalized to their levels in DNA inputs and calculated as a ratio to the
values obtained from the DMSO control samples. Ser2-P ChIP values
were further normalized to the values of total Pol II. Results from three
independent experiments are presented as the mean ± s.e.m. Sequences
of the primers used in ChIP-qPCR assays along with their genomic
locations are listed in Supplementary Table 19.
RNA Interference, siRNAs and antisense-oligonucleotide treatment
For RT-qPCR, cytotoxicity, viability, and apoptosis assays, cells grown
on 6-well plates were transfected with 50 pmol per well of the indicated
siRNA for 48 hours. For co-immunoprecipitation assays, cells grown on
10 cm plates were transfected with 400 pmol per plate of the indicated
siRNA for 48 hours. For ChIP-qPCR assay, cells grown on 15 cm plates
were transfected with 450 pmol per plate of the indicated siRNA for 48
hours. 7SK was depleted for 48 hours using phosphorothioate-modified
antisense DNA oligonucleotide (as7SK), of which sequence was
CCTTGAGAGCTTGTTTGGAGG. 100 pmol per 6-well plate well of the
antisense DNA oligonucleotide was used. Transfections were performed
using Lipofectamine RNAiMAX reagent (Thermo Fisher Scientific, 13778-
150) according to the manufacturer's instructions. RBM7 siRNA #1 had
the sense sequence rGrCrGrUrArArArGrUrCrArGrArArUrGrArArUTT.
RBM7 siRNA #2 had the sense sequence
rGrGrArUrArArArGrGrCrArUrUrGrCrUrUrArATT. Control siRNA was
from Qiagen (AllStars Negative Control siRNA, SI03650318). Efficiency
of the knockdowns were evaluated by Western blotting or RT-qPCR
assays.
Cytotoxicity Assay
HeLa Flp-In, RPE or HFF-1 cells were seeded on 96-well plates 16 hours
before experiment to ensure 80 % confluency. Concentrations of chronic
treatments with 4-NQO were 250 nM (HeLa Flp-In), 500 nM (HFF-1), and
1 mM (RPE). Where indicated, 250 nM of flavopiridol was used. Doses of
UV irradiation were 40 J/m2 (HeLa) and 60 J/m2 (RPE). Cytotoxicity was
evaluated using CellTox Green Cytotoxicity Assay (Promega, G8741).
CellTox Green Dye was added to the cells together with chemicals or
immediately after UV irradiation. Fluorescence was measured at the
indicated time points using PerkinElmer Victor X3 Reader. Results from
three independent experiments are presented as fluorescence values
relative to the untreated control and plotted as the mean ± s.e.m.
Viability Assay
HeLa Flp-In cells were seeded on 96-well plates 16 hours before
experiment to ensure 80 % confluency and subjected to the same
experimental conditions as in cytotoxicity assays. Cell viability was
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examined using alamarBlue Cell Viability Assay (Thermo Fisher
Scientific, DAL 1025). Fresh medium containing the alamarBlue cell
viability reagent was added to the cells two hours prior to the indicated
time points. Fluorescence was measured at the indicated time points
using PerkinElmer Victor X3 Reader. Results from three independent
experiments are presented as fluorescence values relative to the
untreated control and plotted as the mean ± s.e.m.
Apoptosis Assay
HeLa Flp-In cells were seeded on 96-well plates 16 hours before
experiment to ensure 80 % confluency and subjected to the same
experimental conditions as in cytotoxicity assays. Activation of apoptosis
was assessed using RealTime-Glo Annexin V Apoptosis and Necrosis
Assay (Promega, JA1011). Luminescence was measured at the
indicated time points using PerkinElmer Victor X3 Reader. Results from
three independent experiments are presented as luminescence values
relative to the untreated control and plotted as the mean ± s.e.m.
Statistical analysis
Differential gene expression analysis of 4sU-seq data was performed
using edgeR (Robinson et al., 2010). P-values obtained from edgeR were
corrected by multiple testing using the method by Benjamini and
Hochberg (Benjamini and Hochberg, 1995) for adjusting the false
discovery rate (FDR) and a p-value cutoff of 0.01 was applied. Data
shown for all qPCR-based experiments and functional assays were
collected from at least 3 biological replicates as indicated in individual
figure legends and are presented as means ± s.e.m. Statistical
significance and P values were determined by one-tailed Student's t test
performed between the indicated paired groups of biological replicates.
Where the results were not statistically significant, P values are not
indicated.
Data availability
The RBM7 iCLIP data have been deposited to ArrayExpress Archive
(EMBL-EBI) under the accession code E-MTAB-6475. The 4sU-seq data
have been deposited to Gene Expression Omnibus (GEO) repository
(NCBI) under the accession code GSE110272. Tables S3-S6 and S9 are
and other data that support the findings are available upon request from
the corresponding author.
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